We would love to hear your thoughts about our site and services, please take our survey here.
A lot of those sells are buys anyway, I know as one of them is mine. Not long to wait now, Dave will deliver and hopefully we'll lose some of the miserable moaners on here who keep repeating the same thing over and over again.
Your amur minerals second partner below High-tech products are highly competitive in the global market. The output of composite plates and the market share of super-strong offshore steel reached the first in the country; in the complicated foreign trade environment, the export of nickel-based steels will became prominent and became the first steel enterprise in China to import/export high-end nickel-based steels in batches. Standard low-temperature structural steel fills the domestic gap and supplies tens of millions of dollars to the Russian Amur Minerals project.
LeeChang - Amur Minerals CEO interview was not published because of the updated MOD with Jinchuan. New MOD only published on 2019-05-04,evidence below Google out below, CEO was interviewed and according to rumours in China he did accidentally told about nda with Jinchuan and because of it the interview was removed from brr mediauk website. 20 May 2019 Robin Young, CEO, at the @Invest in mining conference in London being interviewed by @brr_mediauk discussing Amur's Kun Manie project following the Company's significant PFS milestone. And following- Amur Mining and Jinchuan Group cooperate to develop nickel sulfide mine 2019-05-04 01:12 Xiaobian: Webmaster Amur Minerals Corporation and China's largest nickel producer Jinchuan Group signed to jointly develop a nickel sulphide project. The Memorandum of Understanding (MOU) involves engineering, design, procurement, and construction of both parties, but the first phase of the detailed investigation phase is carried out by Jinchuan. One of the world's largest sulphide deposits in the Kun-Manie nickel deposit of Amur, located in the Far East of Russia, not far from the Chinese border. “We are pleased to sign a Memorandum of Understanding, which will lead us to maintain long-term cooperation with the world-famous company Jinchuan Group in the nickel industry,” said Amur CEO Robin Young. http : // www .awufengfangguan.com/wufengfangguanziliao-3/2303.html
Avacta plans for exciting cancer immunotherapy (won't post link as won't work on here)
11:21 03 Jun 2019
The group's technology releases chemo directly inside a tumour without exposing the whole body to toxins.
Avacta Group PLC (LON:AVCT) has said it will go to clinic “well ahead of original plans” with a drug candidate that combines its binding protein technology with chemotherapy.
The group's tumour microenvironment activated drug conjugates (TMAC) are a ground-breaking new form of cancer immunotherapy.
Co-invented with Tufts University Medical School of the US, TMAC brings together Avacta’s Affimers with chemotherapies in a single drug using a linker that is designed to only release the chemo in the tumour.
The plan is to gain permission for phase I trial in early 2020 to test the potential new treatment in people with certain types of solid tumours.
Major milestone
The company called the first-in-man study “a major de-risking milestone for the programme”.
"What is so attractive about Avacta's Affimer TMAC programme is that it offers a way to combine chemotherapy with immune checkpoint inhibitors without exposing the whole body to the same level of the chemo-toxin,” said chief executive Alastair Smith.
“Whilst immunotherapies offer great promise for cancer patients, it is well established that only a relatively small sub-group of patients see durable responses to single immune checkpoint therapies. Avacta is directly addressing this urgent clinical need with its novel Affimer TMAC and bispecific programmes,” he added.
Targeted approach
In order to test the TMAC linker in humans for the first time, a chemo treatment called doxorubicin will be modified with the Avacta linker, rendering it inactive and harmless until the linker is split in the tumour, releasing an active cancer-killing agent.
Doxorubicin has well-documented safety issues limiting its dosing, and also putting a cap on the number patients that can be treated with it.
The shares rose 8% on the news, to change hands for 32.12p. Broker finnCap’s target price is 125p.
Analyst Mark Brewer told investors: “Not only is this testing of the TMAC linker well ahead of original plans, but it potentially creates additional sources of non-dilutive funding from licensing the linker to create effective chemotherapeutic pro-drugs that are currently limited by dose-limiting systemic toxicities.
“Proving the enzyme-sensitive linker works in humans also increases the prospect of licensing the Affimer TMAC platform before clinical data are generated from its first Affimer TMAC.”
Avacta's TMAC linker has been shown to increase the maximum tolerated dose by a factor of six in a pre-clinical study in mice.
Avacta well-cashed and on track to begin clinical trial of first Affimer therapeutic next year
11:40 09 Apr 2019 The first Affimer-based therapeutic is PD-L1 is a potential cancer treatment that helps the immune system to identify and attack cancer cells
Affimers have both therapeutic and non-therapeutic uses
Avacta Group PLC (LON:AVCT) remains on track to begin a Phase I clinical trial of its first Affimer therapeutic candidate next year.
Affimers are small, engineered proteins that are capable of binding specific molecular targets, in a similar way to antibodies.
READ: Avacta says partner Moderna takes collaboration to next level
The proteins are smaller, quicker to manufacture and easier to format than antibodies, but they maintain antibody-like biologic activity when binding a target.
Avacta thinks the technology has both therapeutic and non-therapeutic applications.
The AIM company is already using Affimers to develop various potential cancer treatments, while other companies pay to use the technology in their research and diagnostics.
Avacta has selected a PD-L1 inhibitor as the first Affimer-based potential cancer therapeutic that it is taking through the clinic.
PD-L1 is a checkpoint protein that essentially provides a cloak for the cancer cells, helping them to evade detection by the immune system.
Start dosing in Q4 2020
The company is soon to start manufacturing its PD-L1 inhibitor – called AVA004-251 – which will then allow it to file a clinical trial application, asking regulators to let it test the drug on humans.
That filing is expected to happen in late 2020 and the plan is to start dosing the first patients in a Phase I dose escalation study in the final quarter of next year.
“The group remains focused on the key objective of first-time-in-human data for the Affimer therapeutic programme and growing a profitable Affimer reagents business,” said chief executive Alastair Smith.
“First-time-in-human data is a significant value inflection point for the technology and a major de-risking point from a deal-making perspective. The group remains on track, to a tight schedule, to dose first patients in late 2020.”
Plenty of cash in the bank
For the six months ended 31 January, Avacta recorded revenues of £1.0mln (H1 18: £1.5mln), although the new licensing deal with LG Chem will boost second-half numbers.
Unsurprisingly, R&D costs rose to £2.4mln (H1 18: £1.5mln) in the period, which meant operating losses climbed to £5.9mln (H1 18: £4.5mln).
Thanks to an £11.6mln fundraise in August, cash on hand totalled £11.8mln at the end of January (H1 18: £5.2mln).
In a note to clients, analysts at ‘house’ broker finnCap commented: “Significant progress continues to be made in non-therapeutic applications that include at least two in-house diagnostic assay development programmes with further licence
Jesus! There must be some really overstretched traders around by the hysterical “will it be tonight/tomorrow” or “what time does such and such market open” It will arrive when it arrives. Like a bunch of teenage girls on here.
From Tad on LSE - Here we go - latest from Russia!!! 15/03/2019 The Governor of the region presented consolidated proposals from the Amur Region to the National Program for the Development of the Far East Government of the Amur Region Speech by the Governor Attention - social security! Generalized proposals from the region are presented at the meeting of the Legislative Assembly of the region. The Government of the Amur Region made proposals into the program together with the public, the business community, and representatives of the scientific community. Since December 2018, more than 25 thousand proposals from the public have been received. More than 80% of them are reflected in the proposals of the Amur region for inclusion in the National Program. The initiative to develop the National Program for the Development of the Far East in September 2018 at the Eastern Economic Forum was made by Russian President Vladimir Putin. It should determine the state policy for the development of the Far Eastern District until 2025 and, in the future, until 2035. The program is aimed at solving three main tasks: reaching the GDP growth rate in the Far East to 6% per year, stopping the outflow of population from the Far East and improving the quality of life of people and the social development of the regions of the Far East to a level above the average Russian One of the main directions of the program is the implementation of investment and infrastructure projects aimed at ensuring the priority development of the Far Eastern Federal District, as well as the competitiveness of the Far East in comparison with the Asia-Pacific countries. For example, the development of industry is proposed through the implementation of new investment projects that are either already operating in the region or are being proposed for implementation in the future. Among the proposals for the development of the mining industry are the implementation of the development of the Elga gold deposit, the Kun-Manyer copper-nickel deposit and the Ogodzhinskoye coal deposit, as well as the construction of the Erkovetsky open-pit mine. http://moyaokruga.ru/mishvestnik/Articles.aspx?articleId=241011